Curaleaf Holdings (TSX:CURA) is back in focus after reporting second quarter 2026 results on 5 August, with revenue of US$340.1 million and net income of US$12.51 million from continuing operations.
See our latest analysis for Curaleaf Holdings.
Curaleaf Holdings' share price has reacted strongly to the latest quarterly earnings, with a 1-day share price return of 10.42% and a year-to-date share price return of 20.39% at CA$12.93. The 1-year total shareholder return of 78.84% contrasts with weaker multi-year total shareholder returns, suggesting momentum has recently picked up after a more mixed longer-term experience.
If Curaleaf's recent move has you rethinking where growth could come from next, this is a good moment to scan other cannabis-related and wellness plays through the 7 healthcare AI stocks
After Curaleaf Holdings' sharp rebound and return to profitability, the debate shifts to what investors are really pricing in. Is most of the good news already reflected in the stock, or does the valuation still leave meaningful upside?
Most Popular Narrative: 26.9% Undervalued
Curaleaf Holdings is trading at CA$12.93 against a widely followed narrative fair value of about CA$17.70, which frames the latest rally as only part of the story.
Rapid expansion and regulatory breakthroughs in international markets, notably the strong sequential and yearly growth in Germany, new entry into Turkey (an 87-million-person underpenetrated market), and advancements such as the first medically certified EU device, meaningfully increase Curaleaf's total addressable market, diversify revenue streams beyond the saturated U.S. market, and are likely to drive sustained long-term revenue growth.
Want to understand why this narrative still sees upside even after Curaleaf Holdings returned to profit? The story leans heavily on measured revenue growth, a future profit margin upgrade and a premium earnings multiple that usually belongs to higher growth sectors.
Result: Fair Value of CA$17.70 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Curaleaf Holdings still faces pressure from regulatory uncertainty and ongoing losses, and any further shareholder dilution could quickly challenge this bullish valuation story.
Find out about the key risks to this Curaleaf Holdings narrative.
Next Steps
If the mixed sentiment around Curaleaf Holdings has you torn, take a closer look at both sides of the story and act while the details are fresh by weighing the 3 key rewards and 3 important warning signs
Looking for more investment ideas beyond Curaleaf Holdings?
Do not stop with Curaleaf Holdings. Use the Simply Wall Street Screener to quickly spot fresh stock ideas that match your risk comfort, income needs and value focus.
- Target potential mispriced opportunities before the crowd by scanning 11 high quality undervalued stocks built around companies with stronger fundamentals than their share prices may imply.
- Strengthen the resilience of your portfolio by checking out 9 resilient stocks with low risk scores which highlights businesses with lower overall risk profiles.
- Spot earlier stage companies with solid numbers by reviewing the 14 elite penny stocks with strong financials that still pass strict financial quality filters.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com